MX2023005063A - Proteinas de fusion sap fc y metodos de uso. - Google Patents
Proteinas de fusion sap fc y metodos de uso.Info
- Publication number
- MX2023005063A MX2023005063A MX2023005063A MX2023005063A MX2023005063A MX 2023005063 A MX2023005063 A MX 2023005063A MX 2023005063 A MX2023005063 A MX 2023005063A MX 2023005063 A MX2023005063 A MX 2023005063A MX 2023005063 A MX2023005063 A MX 2023005063A
- Authority
- MX
- Mexico
- Prior art keywords
- sap
- methods
- fusion proteins
- relates
- present
- Prior art date
Links
- 108091006020 Fc-tagged proteins Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063108799P | 2020-11-02 | 2020-11-02 | |
| US202163153777P | 2021-02-25 | 2021-02-25 | |
| PCT/US2021/072168 WO2022094630A1 (en) | 2020-11-02 | 2021-11-01 | Sap fc fusion proteins and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005063A true MX2023005063A (es) | 2023-05-12 |
Family
ID=78771272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005063A MX2023005063A (es) | 2020-11-02 | 2021-11-01 | Proteinas de fusion sap fc y metodos de uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12161692B2 (enExample) |
| EP (1) | EP4237083A1 (enExample) |
| JP (1) | JP7856264B2 (enExample) |
| KR (1) | KR20230097061A (enExample) |
| AU (1) | AU2021368272A1 (enExample) |
| BR (1) | BR112023008317A2 (enExample) |
| CA (1) | CA3196766A1 (enExample) |
| IL (1) | IL302388A (enExample) |
| MX (1) | MX2023005063A (enExample) |
| WO (1) | WO2022094630A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
| WO2024153768A1 (en) * | 2023-01-20 | 2024-07-25 | Boehringer Ingelheim International Gmbh | Il-12 fc fusion proteins |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317120D0 (en) | 1993-08-17 | 1993-09-29 | Royal Postgrad Med School | Human serum amyloid p component |
| AU2002225772A1 (en) | 2000-11-27 | 2002-06-03 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| US9200079B2 (en) * | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| CA2682605A1 (en) | 2007-04-18 | 2008-10-30 | Zymogenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| GB0712503D0 (en) | 2007-06-27 | 2007-08-08 | Therapeutics Pentraxin Ltd | Use |
| EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
| UA110323C2 (en) * | 2009-06-04 | 2015-12-25 | Promedior Inc | Derivative of serum amyloid p and their receipt and application |
| HUE041034T2 (hu) | 2009-06-17 | 2019-05-28 | Promedior Inc | SAP-variánsok és alkalmazásuk |
| WO2011119608A1 (en) | 2010-03-26 | 2011-09-29 | University Of Tennessee Research Foundation | Peptides that specifically target amyloid deposits |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| WO2013096847A1 (en) | 2011-12-21 | 2013-06-27 | Promedior, Inc. | Serum amyloid p-antibody fusion proteins |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| US9683017B2 (en) | 2014-07-17 | 2017-06-20 | University Tennessee Research Foundation | Inhibitory peptides of viral infection |
| US10213506B2 (en) | 2014-08-26 | 2019-02-26 | University Of Tennessee Research Foundation | Targeting immunotherapy for amyloidosis |
| US20200148779A1 (en) | 2017-05-25 | 2020-05-14 | Bristol-Myers Squibb Company | MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH |
| JP2021521273A (ja) | 2018-04-12 | 2021-08-26 | メディアファーマ エス．アール．エル． | Ｌｇａｌｓ３ｂｐ抗体−薬剤結合体及びがん治療のためのその使用 |
| BR112023008317A2 (pt) | 2020-11-02 | 2024-02-06 | Attralus Inc | Proteínas de fusão sap fc e métodos de uso |
-
2021
- 2021-11-01 BR BR112023008317A patent/BR112023008317A2/pt unknown
- 2021-11-01 MX MX2023005063A patent/MX2023005063A/es unknown
- 2021-11-01 WO PCT/US2021/072168 patent/WO2022094630A1/en not_active Ceased
- 2021-11-01 KR KR1020237016378A patent/KR20230097061A/ko active Pending
- 2021-11-01 EP EP21815085.2A patent/EP4237083A1/en active Pending
- 2021-11-01 JP JP2023526513A patent/JP7856264B2/ja active Active
- 2021-11-01 US US17/516,601 patent/US12161692B2/en active Active
- 2021-11-01 CA CA3196766A patent/CA3196766A1/en active Pending
- 2021-11-01 IL IL302388A patent/IL302388A/en unknown
- 2021-11-01 AU AU2021368272A patent/AU2021368272A1/en active Pending
-
2024
- 2024-10-25 US US18/927,701 patent/US20250152667A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160831A1 (en) | 2022-05-26 |
| WO2022094630A1 (en) | 2022-05-05 |
| US20250152667A1 (en) | 2025-05-15 |
| CA3196766A1 (en) | 2022-05-05 |
| AU2021368272A1 (en) | 2023-06-08 |
| KR20230097061A (ko) | 2023-06-30 |
| JP7856264B2 (ja) | 2026-05-11 |
| IL302388A (en) | 2023-06-01 |
| US12161692B2 (en) | 2024-12-10 |
| JP2023550287A (ja) | 2023-12-01 |
| BR112023008317A2 (pt) | 2024-02-06 |
| AU2021368272A9 (en) | 2025-03-13 |
| EP4237083A1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021013126A (es) | Variantes de il-15 y usos de las mismas. | |
| WO2021181233A3 (en) | Cd80-fc fusion protein and uses thereof | |
| SA521422089B1 (ar) | c أجسام مضادة مكتسبة للسمة البشرية ضد مجموعة | |
| PH12020552189A1 (en) | Fusion proteins comprising progranulin | |
| IL285269A (en) | Compositions and methods for treating neurocognitive disorders | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| EP3749264C0 (en) | Laser therapy for treatment and prevention of eye diseases | |
| MX2024005705A (es) | Composiciones de liquidos ionicos. | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| PH12022551150A1 (en) | Biparatopic cd73 antibodies | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| IL291725A (en) | Methods and compositions for treating diabetic retinopathy | |
| MX2020000037A (es) | Novedosa proteína terapéutica de fusión enzimática y uso de la misma. | |
| BR112023008317A2 (pt) | Proteínas de fusão sap fc e métodos de uso | |
| BR112023002455A2 (pt) | Anticorpos fgfr3 e métodos de uso | |
| MX2019006444A (es) | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. | |
| IL290891A (en) | Compositions and methods of treating vascular diseases | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения | |
| CR20240265A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| EA202192460A1 (ru) | Синтетические нейромодуляторные пептиды | |
| MX2021008507A (es) | Moleculas que se unen al receptor leucocitario similar a inmunoglobulina subfamilia b miembro 3 (lilrb3) y usos para las mismas. | |
| EP4340880A4 (en) | ANTIBODY-PEPTIDE FUSION PROTEINS FOR THE TREATMENT OF AMYLOID DISORDERS |